VIFOR-PHARMA
5.5.2020 13:03:14 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma announced that its partner, Akebia Therapeutics, Inc ., today reported positive top-line results from INNO2 VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent patients (DD-CKD). Upon successful completion of its phase-III program, which includes Akebia’s studies of vadadustat for the treatment of anemia due to CKD in non-dialysis patients, Akebia plans to submit a New Drug Application (NDA) for vadadustat for the treatment of anemia due to CKD in dialysis dependent and non-dialysis dependent patients, to the U.S. Food and Drug Administration (FDA).
“We are delighted with the positive top-line data from Akebia’s INNO2 VATE global phase-III global study of vadadustat for the treatment of anemia due to CKD in dialysis patients,” comments Stefan Schulze, Vifor Pharma President of the Executive Committee and Chief Operating Officer, “By successfully meeting its primary efficacy and cardiovascular endpoints, we believe the INNO2 VATE data positions vadadustat as a potential new oral standard of care for treating all populations of dialysis patients, including both incident and prevalent dialysis patients with anemia due to CKD, subject to its approval. We look forward to working with Akebia to bring vadadustat, upon approval, to our dialysis patients.”
Vifor Pharma was granted an exclusive license to sell vadadustat to Fresenius Kidney Care dialysis centers and to specific third party dialysis organisations that together account for approximately 60% of the dialysis patients in the US, subject to approval of vadadustat by the FDA and its inclusion in Medicare’s bundled reimbursement model for dialysis, or reimbursement using the Transitional Drug Add-On Payment Adjustment (TDAPA), and a milestone payment by Vifor Pharma.
About Akebia’s Global phase-III INNO2 VATE Program
Akebia’s public announcement highlighted that its global INNO2 VATE program is a cardiovascular outcomes program which includes two separate phase-III studies (Correction/Conversion and Conversion ) and which collectively enrolled 3,923 dialysis-dependent patients with anemia due to chronic kidney disease (CKD). Both INNO2 VATE studies are global, multicenter, open label (sponsor blinded), active-control (darbepoetin alfa- an injectable erythropoiesis stimulating agent (ESA)), non-inferiority studies. According to Akebia’s announcement: “Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2 VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat also achieved the primary safety endpoint of the INNO2 VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is a composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2 VATE studies. Each analysis was measured against non-inferiority (NI) margins agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).”
About Vadadustat
Vadadustat is Akebia’s oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Please visit https://akebia.com/pr-552020/ to access the complete public announcement from Akebia Therapeutics, which does not form a part of this release.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Announces 2027 Prism Awards Finalists for Best Photonics Products4.11.2026 21:22:00 CET | Press release
The 19th annual competition recognizes groundbreaking technologies around the globe SPIE, the international society for optics and photonics, has announced finalists in the seven categories for the 2027 Prism Awards, which recognize remarkable new photonics products on the market. Winners will be announced during the awards ceremony at SPIE Photonics West on 3 February 2027 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104613876/en/ SPIE has announced the finalists for the 2027 SPIE Prism Awards, which recognize optics and photonics innovations. Recipients will be announced at the awards ceremony on 3 February 2027 at SPIE Photonics West. During the Prism Awards, SPIE will also announce the winner of the SPIE Catalyst Award, honoring a for-profit company with social or environmental programs that have made significant advances in workplace opportunity, community engagement, or environmental
Every Critical System Should Have a Backup: Elliptic Opens Up Fast Track Monitoring to the Crypto Industry4.11.2026 21:07:00 CET | Press release
Fast Track Monitoring, powered by Elliptic Lens, gives compliance teams screening continuity when they need it most Elliptic, the leader in on-chain risk management, is making Fast Track Monitoring available to firms with digital assets exposure as a back up screening option for firms that need business continuity, if their primary screening service is unavailable and they need a second option. Criminals are increasingly using AI to scale their attacks, so on-chain risk now moves at machine speed. Compliance teams need the broadest range of options to keep screening every wallet and transaction, and a second screening provider builds resilience into any on-chain risk management approach. Elliptic recommends every business has one in place. Organizations that rely on a single screening vendor can also still need a second option. Fast Track Monitoring gives compliance teams real-time wallet and transaction screening powered by Elliptic Lens, with a clear, explainable risk score on every
Smartsheet Adds New AI Agents, Integrations and Security Advancements at ENGAGE 20264.11.2026 19:00:00 CET | Press release
New AI advancements take over status reports and routine follow-ups, powered by 20 years of workflow intelligence seeing how work happens and where it drifts, with enterprise security and governance built-in Smartsheet, the AI-powered enterprise work management platform, today announced new platform capabilities at ENGAGE 2026, its annual customer conference. The company introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift: the costly gap between what an organization sets out to deliver and what it actually delivers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104562370/en/ Today, Smartsheet introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift. AI has helped teams move faster, but it is also widening execution drift. As AI agents join people, partners and systems in doing the work, three problem
MultiBank Exchange Holding Forms Predominantly Emirati Board as Platform Records US$500 Billion in Monthly Trading Volume4.11.2026 18:54:00 CET | Press release
MultiBank Group has announced the formation of a predominantly Emirati Board of Directors for MultiBank Exchange Holding, the first interbank trading platform in the BRICS and emerging countries, which achieved in October 2026 a turnover of over US$ 0.5 Trillion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104483253/en/ Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member; H.E. Sheikh Mohammed bin Saqr bin Rashid Al Nuaimi, Board Member; H.E. Mohammed Al Hakim, Vice Chairman of the Board; H.E. Ali bin Khalid bin Zayed Al Falasi, Board Member; H.E. Rashid Sultan Al Malik, Board Member; Mr. Majid Al Ghaslan, Board Member; and Mr. David Ogg, Board Member. Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member. H.E. Sheikh Moham
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 18:00:00 CET | Press release
High speed data transfers send SES’s CEO to space, advancing meoSphere optical network SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom